Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
대표청구항▼
1. A compound having the formula (XXVI): wherein: T2 is a group comprising a conjugate linker, a cleavable moiety, and an oligomeric compound. 2. The compound of claim 1, wherein the conjugate linker comprises an amine, an amide, an ester, an ether, a pyrrolidine, ethylene glycol, a polyamide, or a
1. A compound having the formula (XXVI): wherein: T2 is a group comprising a conjugate linker, a cleavable moiety, and an oligomeric compound. 2. The compound of claim 1, wherein the conjugate linker comprises an amine, an amide, an ester, an ether, a pyrrolidine, ethylene glycol, a polyamide, or a disulfide bond. 3. The compound of claim 1, wherein the conjugate linker has the formula: 4. The compound of claim 1, wherein T2 has the formula: wherein: CM is the cleavable moiety and T3 comprises the oligomeric compound. 5. The compound of claim 4, wherein T2 has the formula: wherein: T3 is the oligomeric compound. 6. The compound of claim 5, wherein the oligomeric compound is a modified oligonucleotide. 7. The compound of claim 6, wherein the modified oligonucleotide consists of 15 to 24 linked nucleosides wherein at least one nucleoside is a modified nucleoside. 8. The compound of claim 6, wherein the modified oligonucleotide comprises at least one modified nucleoside selected from among: a 2′-MOE nucleoside, a 2′-OMe nucleoside, a 2′-F nucleoside, a (4′-CH2—O-2′) bicyclic nucleoside, a (4′-(CH2)2-O-2′) bicyclic nucleoside, a (4′-C(CH3)H—O-2′) bicyclic nucleoside; and a morpholino. 9. The compound of claim 8, wherein the modified oligonucleotide has a gapmer sugar motif comprising: a 5′-region consisting of 2-8 linked 5′-region nucleosides, wherein each 5′-region nucleoside is a modified nucleoside;a 3′-region consisting of 2-8 linked 3′-region nucleosides, wherein each 3′-region nucleoside is a modified nucleoside; anda central region between the 5′-region and the 3′-region consisting of 5-10 linked central region nucleosides, each independently selected from among: a modified nucleoside and an unmodified deoxynucleoside, wherein the 5′-most central region nucleoside is an unmodified deoxynucleoside and the 3′-most central region nucleoside is an unmodified deoxynucleoside. 10. The compound of claim 9, wherein the modified oligonucleotide has a chemical motif selected from among: MsMy(Ds)0-1(DsDs)(3-5)MsMMsMy(Ds)0-1(DsDs)(3-5)MyMsMMsMy(Ds)0-1(DsDs)(3-5)MyMyMsMMsMy(Ds)0-1(DsDs)(3-5)MyMyMyMsMMsMyMy(Ds)0-1(DsDs)(3-5)MsMMsMyMy(Ds)0-1(DsDs)(3-5)MyMsMMsMyMy(Ds)0-1(DsDs)(3-5)MyMyMsMMsMyMy(Ds)0-1(DsDs)(3-5)MyMyMyMsMMsMyMyMy(Ds)0-1(DsDs)(3-5)MsMMsMyMyMy(Ds)0-1(DsDs)(3-5)MyMsMMsMyMyMy(Ds)0-1(DsDs)(3-5)MyMyMsMMsMyMyMy(Ds)0-1(DsDs)(3-5)MyMyMyMsMMsMyMyMyMy(Ds)0-1(DsDs)(3-5)MsMMsMyMyMyMy(Ds)0-1(DsDs)(3-5)MyMsMMsMyMyMyMy(Ds)0-1(DsDs)(3-5)MyMyMsM; andMsMyMyMyMy(Ds)0-1(DsDs)(3-5)MyMyMyMsM;wherein each M is independently a modified nucleoside, each D is a deoxynucleoside; each s is a phosphorothioate internucleoside linkage, and each y is independently either a phosphodiester internucleoside linkage or a phosphorothioate internucleoside linkage, provided that at least one y is a phosphodiester internucleotide linkage. 11. The compound of claim 9, wherein the 5′-region consists of 2-5 linked 5′-region nucleosides; the 3′-region consists of 2-5 linked 3′-region nucleosides; and the central region consists of 8-10 central region nucleosides. 12. The compound of claim 11, wherein each internucleoside linkage of the modified oligonucleotide is either a phosphorothioate internucleoside linkage or a phosphodiester internucleoside linkage. 13. The compound of claim 11, wherein the modified oligonucleotide is attached to the remainder of the compound at the 5′-end of the modified oligonucleotide. 14. The compound of claim 13, wherein the modified oligonucleotide is single-stranded. 15. The compound of claim 14, wherein the modified oligonucleotide is complementary to a target nucleic acid. 16. The compound of claim 15, wherein the target nucleic acid is selected from among: mRNA, pre-mRNA, micro-RNA, and long non-coding RNA. 17. A compound having the formula: wherein X is O or S;wherein Bx is a heterocyclic base moiety;and wherein T4 is a nucleoside, a monomeric subunit, or an oligomeric compound. 18. The compound of claim 17, wherein X is S. 19. The compound of claim 17, wherein T4 is an oligomeric compound, and wherein the oligomeric compound is a modified oligonucleotide. 20. The compound of claim 19, wherein the modified oligonucleotide is a gapmer. 21. The compound of claim 20, wherein the modified oligonucleotide activates RNase H when bound to a complementary target nucleic acid. 22. The compound of claim 21, wherein the at least one modified nucleoside is a modified nucleoside selected from a 2′-F nucleoside, a 2′-OCH3 nucleoside, a 2′-O(CH2)2OCH3 nucleoside, a 2′-OC(CH3)H-4′ nucleoside, and a 2′-OCH2-4′ nucleoside. 23. The compound of claim 22, wherein the modified nucleoside is a 2′-O(CH2)2OCH3 nucleoside. 24. A compound having the formula: wherein X is O or S;wherein Bx is a heterocyclic base moiety;wherein T4 is a nucleoside, a monomeric subunit, or an oligomeric compound. 25. The compound of claim 24, wherein X is S. 26. The compound of claim 24, wherein T4 is an oligomeric compound, and wherein the oligomeric compound is a modified oligonucleotide. 27. The compound of claim 26, wherein the modified oligonucleotide is a gapmer. 28. The compound of claim 27, wherein the modified oligonucleotide activates RNase H when bound to a complementary target nucleic acid. 29. The compound of claim 28, wherein the at least one modified nucleoside is a modified nucleoside selected from a 2′-F nucleoside, a 2′-OCH3 nucleoside, a 2′-O(CH2)2OCH3 nucleoside, a 2′-OC(CH3)H-4′ nucleoside, and a 2′-OCH2-4′ nucleoside. 30. The compound of claim 29, wherein the modified nucleoside is a 2′-O(CH2)2OCH3 nucleoside.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (97)
Huynh Dinh Tam (Croissy/Seine FRX) Gouyette Catherine (Vanves FRX) Igolen Jean (Le Mesnil St. Denis FRX), 2,N6-disubstituted and 2,N6-trisubstituted adenosine-3′-phosphoramidites.
Cowsert, Lex M.; Wyatt, Jacqueline R.; Freier, Susan M.; Monia, Brett P.; Butler, Madeline M.; McKay, Robert, Antisense modulation of PTP1B expression.
Sanghvi Yogesh S. (Carlsbad CA) Cook Phillip D. (Carlsbad CA), Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling.
Cook Phillip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA) Vasseur Jean J. (San Marcos CA) Debart Francoise (Montpellier FRX), Backbone modified oligonucleotide analogues.
Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Ramsay Shaw Barbara (Durham NC), Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same.
Bhanot, Sanjay; Geary, Richard S.; McKay, Robert; Monia, Brett P.; Seth, Punit P.; Siwkowski, Andrew M.; Swayze, Eric; Wancewicz, Edward, Compounds and methods for modulating expression of PCSK9.
Bhat, Balkrishen; Xia, Jie; Seth, Punit P.; Vasquez, Guillermo; Migawa, Michael T.; Allerson, Charles; Prakash, Thazha P.; Swayze, Eric E., Compounds and methods for synthesis of bicyclic nucleic acid analogs.
Ts'o, Paul O. P.; Duff, Robert; Deamond, Scott, Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use.
Ts'O,Paul O. P.; Duff,Robert; Deamond,Scott, Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use.
Froehler Brian (Belmont CA) Matteucci Mark (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified purines.
Froehler Brian (Belmont CA) Wagner Rick (Belmont CA) Matteucci Mark (Burlingame CA) Jones Robert J. (Millbrae CA) Gutierrez Arnold J. (Sandy Lane CA) Pudlo Jeff (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines.
Rogers Thomas E. (Manchester MO) Gray Steven H. (Ellisville MO) Devadas Balekudru (Chesterfield MO) Adams Steven P. (St. Charles MO), Improved probes using nucleosides containing 3-dezauracil analogs.
Benner Steven A. (Hadlaubstrasse 151 CH-8006 Zurich CHX), Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Freier, Susan M.; Crooke, Rosanne M.; Graham, Mark J.; Lemonidis, Kristina L.; Bhanot, Sanjay; Tribble, Diane; Watt, Andrew T., Methods for treating hypercholesterolemia.
Freier, Susan M.; Crooke, Rosanne M.; Graham, Mark J.; Lemonidis, Kristina L.; Bhanot, Sanjay; Tribble, Diane; Watt, Andrew T., Methods for treating hypercholesterolemia.
Froehler Brian ; Wagner Rick ; Matteucci Mark ; Jones Robert J. ; Gutierrez Arnold J. ; Pudlo Jeff, Methods of using oligomers containing modified pyrimidines.
Yurkovetskiy, Aleksandr; Yin, Mao; Lowinger, Timothy B.; Cabral, Carolina B.; Hammond, Charles E.; Stevenson, Cheri A., Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof.
Ts\o Paul O. P. (2117 Folkstone Rd. Lutherville MD 21093) Miller Paul S. (225 Hopkins Rd. Baltimore MD 21212), Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof.
Cook Philip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA), Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression.
Baxter Anthony D. (Northwich GB2) Baylis Eric K. (Stockport GB2) Collingwood Stephen P. (Westhoughton GB2) Taylor Roger J. (Stretford GB2) Mesmaeker Alain (Kanerkinden CHX) Schmit Chantal (Basel CHX), Nucleoside phosphinate compounds and compositions.
Letsinger Robert L. (Wilmette IL) Gryaznov Sergei M. (San Mateo CA), Oligodeoxyribonucleotides including 3′-aminonucleoside-phosphoramidate linkages and terminal 3′-amino groups.
Rozema, David B.; Wakefield, Darren H.; Lewis, David L.; Wolff, Jon A.; Blokhin, Andrei V.; Benson, Jonathan D.; Carlson, Jeffrey C.; Hadwiger, Philipp; Kitas, Eric A.; Hoffmann, Torsten; Jahn-Hofmann, Kerstin; Mohr, Peter; Mueller, Hans Martin; Ott, Guenther; Roehl, Ingo, Peptide-based in vivo siRNA delivery system.
Rozema, David B.; Hagstrom, James E.; Klein, Jason; Lewis, David L.; Monahan, Sean D.; Wakefield, Darren H.; Wolff, Jon A.; Wong, So, Polyconjugates for in vivo delivery of polynucleotides.
Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Ramsay Shaw Barbara (Durham NC), Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates.
Hawkins Mary E. (Potomac MD) Pfleiderer Wolfgang (Konstanz MD DEX) Davis Michael D. (Rockville MD) Balis Frank (Bethesda MD), Pteridine nucleotide analogs as fluorescent DNA probes.
Cook Phillip Dan (Carlsbad CA) Manoharan Muthiah (Carlsbad CA) Ramasamy Kanda S. (Laguna Hills CA), Substituted purines and oligonucleotide cross-linking.
Summerton James E. (Corvallis OR) Weller Dwight D. (Corvallis OR), Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages.
Rozema, David B.; Wakefield, Darren H.; Blokhin, Andrei V.; Benson, Jonathan D.; Li, Zhen; Pei, Tao; Fleitz, Fred, Targeting ligands for therapeutic compounds.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.